Black Diamond Therapeutics vs Fennec Pharmaceuticals
BDTX and FENC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and FENC compare
Fennec Pharmaceuticals is the larger company, worth 4.8 times as much as Black Diamond Therapeutics ($407M against $84.5M).
Fennec Pharmaceuticals grew revenue faster over the last twelve months (71.1% versus −100% for Black Diamond Therapeutics).
Fennec Pharmaceuticals scores higher on the StockData Score (8 against 7 for Black Diamond Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | FENC |
|---|---|---|
| Size and price | ||
| Market cap | $84.5M | $407M |
| Share price | $1.47 | $11.62 |
| Change, 1 year | −69.8% | 49.4% |
| Change, 5 years | −79.3% | 18.3% |
| Beta (5Y) | 2.47 | 0.82 |
| Employees | 21 | 35 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 387× |
| P/S | – | 6.1× |
| P/B | 1.0× (better) | 8.3× |
| EV/EBITDA | – | 96.5× |
| Fair value | – | $3.92 |
| Margin of safety | – | −196% |
| Growth | ||
| Revenue growth (TTM) | −100% | 71.1% (better) |
| Revenue growth, 5Y average | – | 195% |
| Net income growth (TTM) | −305% | – |
| EPS growth (TTM) | −311% | – |
| Profitability | ||
| Operating margin | – | 5.6% |
| Net margin | – | 3.1% |
| Return on equity | −41.1% | 9.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | 11.7× |
| Current ratio | 6.92 (better) | 6.11 |
| Altman Z-score | −4.71 | 5.30 (better) |
| Piotroski F-score | 7 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 46.5% |
| Held by insiders | 9.1% | – |
| Insider net buying, 12 months | – | −$9.6M |
| Short interest, % of float | 9.8% | – |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- FENC stock overview
- FENC income statement
- FENC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.